Artiva Biotherapeutics, Inc.
NASDAQ:ARTVBiotechnology
-$0.34 today
- Market cap
- $186.36M
- Beta
- 2.40
- P/E (TTM)
- -2.7
- EPS (TTM)
- -$3.53
Volume 0.97M
Average 0.48M
ARTV Weighted Avg Shares (Diluted)
Average shares outstanding including dilutive securities, used to calculate diluted EPS.
Artiva Biotherapeutics, Inc.NASDAQ: ARTV
Weighted Avg Shares (Diluted) · Q1 FY2026 · quarter ended Mar 2026
Weighted avg shares (diluted) grows in line with its trailing trend
Q1 FY2026 weighted avg shares (diluted) of 24.68M shares rose 1.4% year over year, in line with the +1.8% change in trailing-twelve-month weighted avg shares (diluted). Sequentially, it rose 1.0% from the prior quarter. Over 3 fiscal years it compounded at +11.6% a year.
Context
- Weighted avg shares (diluted) increased in 3 of the last 3 fiscal years.
- FY2025 was the highest annual figure in the 4 fiscal years shown.
What to watch
Whether quarterly growth recovers from +1.4% toward the trailing-twelve-month pace of +1.8%.
Sources:Income StatementText generated from reported figures; not investment advice.
Weighted Avg Shares (Diluted) history
Shares · from the income statement
- Latest · FY2025
- 24.44M USD
- Year-over-year change
- +0.3%
- 4-year CAGR
- +8.6%
| Period | Period end | Weighted Avg Shares (Diluted) | YoY change |
|---|---|---|---|
| FY2025 | 2025-12-31 | 24.44M | +0.3% |
| FY2024 | 2024-12-31 | 24.36M | +4.6% |
| FY2023 | 2023-12-31 | 23.28M | +32.4% |
| FY2022 | 2022-12-31 | 17.58M | +0.0% |
| FY2021 | 2021-12-31 | 17.58M | — |
Weighted Avg Shares (Diluted) vs competitors
How ARTV compares with its peers on the latest reported figures
- ARTV's LTM Mar 2026 weighted avg shares (diluted) of 24.5M shares is the 7th highest of the 9 companies compared; the peer median is 61M shares.
- Its year-over-year change of +1.8% is the 6th highest of 9, against a peer median of +8.6%.
- Over three fiscal years its annual growth of +11.6% compares with a peer median of +15.9%.
| Company | Period | LTM | YoY | 3-year CAGR |
|---|---|---|---|---|
| LTM Mar 2026 | 84.8M | +66.7% | +18.0% | |
| LTM Mar 2026 | 71.52M | +0.4% | +10.8% | |
| LTM Mar 2026 | 68.86M | +14.8% | +15.0% | |
| LTM Mar 2026 | 66.33M | +37.1% | +16.8% | |
| FY2025 | 55.66M | +0.8% | +0.4% | |
| LTM Mar 2026 | 53.9M | +2.3% | +9.7% | |
ARTVArtiva Biotherapeutics, Inc. | LTM Mar 2026 | 24.5M | +1.8% | +11.6% |
| LTM Mar 2026 | 12.13M | +60.9% | +63.6% | |
| LTM Mar 2026 | 6.42M | -22.0% | +18.8% | |
| Peer median (excluding ARTV) | 61M | +8.6% | +15.9% | |
Competitors are the stored peer set for ARTV. Fiscal calendars differ, so each company's latest period is shown. Text is generated from reported figures; not investment advice.
Income Statement
Metric | FY2021 Dec 2021 | FY2022 Dec 2022 | FY2023 Dec 2023 | FY2024 Dec 2024 | FY2025 Dec 2025 |
|---|---|---|---|---|---|
| Revenue | 2M | 4.93M | 33.49M | 251K | 0 |
| Cost of Revenue | 0 | 0 | 0 | 0 | 2.6M |
| Gross Profit | 2M | 4.93M | 33.49M | 251K | (2.6M) |
| Gross Margin | 100.0% | 100.0% | 100.0% | 100.0% | — |
| Research & Development | 42.41M | 43.98M | 50.25M | 50.33M | 69.54M |
| Selling, General & Admin | 12.86M | 20.78M | 13.91M | 17.21M | 20.27M |
| Operating Expenses | 55.27M | 64.76M | 64.16M | 67.53M | 88.01M |
| Depreciation & Amortization | 248K | 1.16M | 2.27M | 2.43M | 2.6M |
| EBITDA | (71.58M) | (57.18M) | (25.36M) | (56.06M) | (81.27M) |
| EBITDA Margin | -3575.3% | -1159.5% | -75.7% | -22335.5% | — |
| Operating Income | (53.27M) | (59.83M) | (30.67M) | (67.28M) | (90.61M) |
| Operating Margin | -2660.9% | -1213.3% | -91.6% | -26805.6% | — |
| Interest Income | 0 | 1.29M | 2.54M | 5.35M | 5.96M |
| Interest Expense | 0 | 0 | 0 | 0 | 0 |
| Other Income / Expenses | (18.55M) | 1.49M | 3.05M | 8.79M | 6.75M |
| Income Before Tax | (71.83M) | (58.34M) | (27.62M) | (58.49M) | (83.87M) |
| Pre-Tax Margin | -3587.7% | -1183.0% | -82.5% | -23304.0% | — |
| Income Tax Expense | 0 | 53K | 72K | 0 | 0 |
| Net Income | (71.83M) | (58.39M) | (27.7M) | (58.49M) | (83.87M) |
| Net Margin | -3587.7% | -1184.1% | -82.7% | -23304.0% | — |
| EPS (Basic) | (4.08) | (3.32) | (1.19) | (5.20) | (3.43) |
| EPS (Diluted) | (4.08) | (3.32) | (1.19) | (5.20) | (3.43) |
| Weighted Avg Shares | 17.58M | 17.58M | 23.28M | 24.36M | 24.44M |
| Weighted Avg Shares (Diluted) | 17.58M | 17.58M | 23.28M | 24.36M | 24.44M |
Artiva Biotherapeutics, Inc.
NASDAQ:ARTV
Intrinsic Alpha fair value
Locked
Current Price
$3.77
Unlock the intrinsic value to see where the current price sits on the valuation runway.
Valuation runway
LockedGet the intrinsic value and margin of safety with a free account.
Continue the stock analysis
Jump to another research area for this company.